Tilray Inc. (TLRY)

43.88
NASDAQ : Health Technology
Prev Close 44.79
Day Low/High 43.74 / 45.43
52 Wk Low/High 20.10 / 300.00
Avg Volume 1.64M
Exchange NASDAQ
Shares Outstanding 80.56M
Market Cap 4.35B
EPS -0.80
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

2 Big Earnings Reports I'll Be Watching This Week

2 Big Earnings Reports I'll Be Watching This Week

A huge week is coming up for these well-known stocks.

Short Interest Monitor on Tilray

Cause for Caution? Top Executives Selling Tilray Stock

Cause for Caution? Top Executives Selling Tilray Stock

It might not be time to panic yet about Tilray, but there's likely a problem ahead.

With Tilray, You Won't Win Any Valuation Arguments

With Tilray, You Won't Win Any Valuation Arguments

Short interest is back in the low single digits while Tilray still enjoys one of the smallest floats for a cannabis company.

Tilray Touts Global Ambition as Erosion of Canadian Market Expected

Tilray Touts Global Ambition as Erosion of Canadian Market Expected

A key aspect of the international expansion is the company's recent acquisition of hemp-food producer Manitoba Harvest in February.

Tilray Is Not My Favorite Canadian Cannabis Stock

Tilray Is Not My Favorite Canadian Cannabis Stock

Apparently, this game is all about growth right now. It certainly is not about margins.

Kass: Tilray Is Promising but I Prefer This Other Stock in the Pot Space

Kass: Tilray Is Promising but I Prefer This Other Stock in the Pot Space

Tilray will not be cash flow positive for another 2-3 years - that's not quick enough progress for me given its $7 billion dollar capitalization.

Tilray Has Rebased and Looks Poised to Rally Again - Consider Buying Strength

Tilray Has Rebased and Looks Poised to Rally Again - Consider Buying Strength

Let's check out the charts and indicators for this so-called pot play.

Stock of the Day - Tilray

Pot stocks like Tilray have very ambitious valuations but the potential upside (in mergers and, fundamentally in food, drink, supplemental and medical applications) are undeniably immense. The view of a possible rapid rise in revenues and profits (a...

Tilray Stock Lights Up as Partnerships Obscure Profitability Problem

Tilray Stock Lights Up as Partnerships Obscure Profitability Problem

The move was helped by the TLRY's deals with AB InBev for beverages and Novartis for medical applications.

3 Important Earnings Reports I'll Be Watching This Week

3 Important Earnings Reports I'll Be Watching This Week

This quarter is a heavy test for Tilray because of the stock's lofty valuation.

Chart of the Day: Vetting the Value of Cannabis Companies

Chart of the Day: Vetting the Value of Cannabis Companies

Assessing Aurora and its peers, strictly on the numbers.

Just How Hot Is Cannabis?

Aurora Cannabis' Is a Beast but the Stock Has Entered a Tricky Area Now

Aurora Cannabis' Is a Beast but the Stock Has Entered a Tricky Area Now

Aurora Cannabis' hiring of deal maker Nelson Peltz opens up a wealth of new possibilities for the Canadian pot company.

Jim Cramer: Buy Aurora Cannabis Because Nelson Peltz Knows What Can Go Right

Jim Cramer: Buy Aurora Cannabis Because Nelson Peltz Knows What Can Go Right

I know that Nelson is fascinated by the medicinal properties chiefly as a replacement for opioids, the scourge of this country.

Aurora Cannabis Could Triple in the Months Ahead

Aurora Cannabis Could Triple in the Months Ahead

The price of ACB is moving up today and a fresh look at the charts and indicators seems like a good idea.

Melius Research Launches Cannabis Industry Coverage

Melius Research Launches Cannabis Industry Coverage

In its first report on cannabis companies, Melius says prices are high.

Acreage Wants to Be Your All-American Cannabis Company

Acreage Wants to Be Your All-American Cannabis Company

In an industry where Canadian companies have been grabbing the headlines, New York-based Acreage Holdings has methodically built itself into the largest American cannabis firm.

Short-Selling Is Really Hard. Just Ask Citron Research

Short-Selling Is Really Hard. Just Ask Citron Research

Examining the influential short-sellers' big winners and losers provides important insights into trading and investing.

S&P 500 Is Testing Resistance, and How to Play Activision: Market Recon

S&P 500 Is Testing Resistance, and How to Play Activision: Market Recon

China trade discussions will continue to be a key driver in Wednesday's market action.

Pot Stocks Fade as Momentum Cools

Pot Stocks Fade as Momentum Cools

There are some big shifts Wednesday in names that have recently been the hottest.

Cannabis Stocks Are Getting Their Second Wind

Cannabis Stocks Are Getting Their Second Wind

Let's check out the charts of four big names in the space.

Excuse Me, Would You Like Some Cannabis With Your Coffee?

Excuse Me, Would You Like Some Cannabis With Your Coffee?

CBD could make coffee an around the clock craze.

Chart of the Day, Part 2: A Closer Look at Constellation's Big Cannabis Bet

Chart of the Day, Part 2: A Closer Look at Constellation's Big Cannabis Bet

Canopy Growth's smoking engine won't necessarily ensure smooth sailing for Constellation.

Not Up In Smoke (Part Deux)

"One last thing." -- Lt. Columbo I have recently been focused on Canopy Growth Corp. CGC as an interesting speculation in 2019 (I have been adding over the last few days). In fact, I commented today on the stock. After the close, Tilray was upgraded...

Real Money Goes Behind the Scenes of the Budding Cannabis Industry

Real Money Goes Behind the Scenes of the Budding Cannabis Industry

In the interest of due diligence, we went and took a close look at the ground floor of the newest investment craze.